All In Biotech

Drug Trial Radar · NCT05597839

Study of DF9001 in Patients With Advanced Solid Tumors

A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF9001 as a Monotherapy and in Combination Therapies in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications

Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 15, 2022

Primary completion

Aug 15, 2025

Study completion Aug 15, 2025

Sponsor

Lead sponsor
Dragonfly TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors (monotherapy and in combination with pembrolizumab).

Conditions

  • Solid Tumor, Adult

Interventions

  • DF9001Drug

    Immunotherapy agent targeting NK cells.

  • KEYTRUDA® (pembrolizumab)Drug

    Anti-PD-1 immunotherapy agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number, severity, and duration of treatment-related adverse events (TRAEs) according to NCI-CTCAE v5.0.Time frame: Screening visit up to 28 days after last treatment on the study.
  2. Number of patients with AEs and TRAEs.Time frame: Screening visit up to 28 days after last treatment on the study.
  3. Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocolTime frame: First 4 weeks of treatment for each subject.
  4. Assess Overall Response RateTime frame: Through 90 days after completion of the study, an average of 1 year.

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Gilbert, Arizona

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • UC Irvine Medical Center

    Irvine, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • University of Louisville Hospital

    Louisville, Kentucky

  • Mayo Clinic Minnesota

    Rochester, Minnesota

  • AMR Kansas City

    Kansas City, Missouri

  • Rutgers

    New Brunswick, New Jersey

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UMPC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.